This page shows the latest Brintellix news and features for those working in and with pharma, biotech and healthcare.
EMA backs Lundbeck's Brintellix in depression. Drug recommended for approval to treat major depressive episodes in adults. ... In the latest round of EU drug recommendations, Lundbeck won backing for the use of Brintellix in the treatment of adult
Lundbeck buoyed by Brintellix approval in US. FDA gives green light for to Cipralex/Lexapro successor in depression. ... Lundbeck was celebrating yesterday after the FDA approved its new antidepressant Brintellix, a successor to the big-selling
Lundbeck and Takeda submit depression drug for US approval. Brintellix could help Lundbeck overcome loss of patent protection for Lexapro/Cipralex. ... Lundbeck's plans to find a replacement for its big-selling antidepressant Lexapro/Cipralex continue
Antidepressant Brintellix, launched late in 2013 by Takeda and Lundbeck, was the second most advertised drug in January.
Much now hangs on the success of this drug and a couple of other late-stage products, such as vortioxetine for depression ( licensed from Lundbeck) - recently approved as Brintellix in the US -
All eyes are on the performance of Cipralex successor Brintellix ( vortioxetine) - which was approved at the end of September - along with other recent launches, such as alcoholism therapy Selincro ( nalmefene) and ... Meanwhile, Selincro's first launch (
More from news
Approximately 3 fully matching, plus 10 partially matching documents found.